Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CERo Therapeutics Holdings, Inc. - Common Stock (NQ:CERO)

0.6500 -0.0799 (-10.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 650,535
Open 0.7020
Bid (Size) 0.6600 (55)
Ask (Size) 0.6700 (3)
Prev. Close 0.7299
Today's Range 0.6496 - 0.7100
52wk Range 0.5338 - 126.05
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire

Performance

YTD
-89.3%
-89.3%
1 Month
-22.2%
-22.2%
3 Month
-66.5%
-66.5%
6 Month
-90.7%
-90.7%
1 Year
-99.4%
-99.4%

More News

Read More
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
Top stock movements in today's session.
Via Chartmill
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Thursday's session: top gainers and losers
Via Chartmill
Keep an eye on the top gainers and losers in Thursday's session.
Via Chartmill
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Which stocks are gapping on Thursday?
Via Chartmill
Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Top movers in Thursday's pre-market session
Via Chartmill
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish
Via Stocktwits
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is CERo Therapeutics Holdings, Inc. - Common Stock publicly traded?
Yes, CERo Therapeutics Holdings, Inc. - Common Stock is publicly traded.
What exchange does CERo Therapeutics Holdings, Inc. - Common Stock trade on?
CERo Therapeutics Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for CERo Therapeutics Holdings, Inc. - Common Stock?
The ticker symbol for CERo Therapeutics Holdings, Inc. - Common Stock is CERO on the Nasdaq Stock Market
What is the current price of CERo Therapeutics Holdings, Inc. - Common Stock?
The current price of CERo Therapeutics Holdings, Inc. - Common Stock is 0.6500
When was CERo Therapeutics Holdings, Inc. - Common Stock last traded?
The last trade of CERo Therapeutics Holdings, Inc. - Common Stock was at 05/09/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.